Discover how Cizzle Bio, Inc. is transforming lung cancer detection with a simple blood test for the CIZ1B Biomarker. Learn about our innovative approach to early-stage lung cancer diagnosis, addressing the urgent need for effective screening methods
The study concludes that a new blood test, tge RNA blood test, may be able to detect lung cancer in its early stages. RNA fingerprints from peripheral blood samples of a cohort of smokers with lung cancer...
is key LungLife AI is a developer of clinical diagnostic solutions designed to make a significant impact in the early detection of lung cancer, the deadliest cancer globally. Using a minimally invasive blood draw, our LungLB®test is designed to deliver additional information to clinicians who a...
Innovation in early diagnosis of cancer DiagnoLung® DiagnoLung® is a minimally invasive blood-based test for the early detection of lung cancer. Besides, it can be a screening tool for high risk population. Under clinical validation View Product PreveCol® PreveCol® is an innovative...
These results argue that the miR-Test might represent a useful tool for lung cancer screening in high-risk individuals. 展开 关键词: LUNG cancer diagnosis BLOOD testing MICRORNA EARLY detection of cancer MORTALITY prevention DOI: 10.1093/jnci/djv063 被引量: 91 ...
Most of the time, the blood-derived mutations are not cancer-initiating, and "false positive" results often lead to unnecessary overtesting and overtreatments. To develop the new test, Velculescu and colleagues obtained blood samples from 200 patients with breast, lung, ovarian and colorectal can...
“This method could serve as the basis for further development of a highly accurate and minimally invasive blood-based screening test for a wider population.” Patients with lung cancer whose disease has spread to distant sites have a survival rate of 6% at 5 years, while those with localized...
Armed with such a blood test, doctors might then use mammograms only after cancer has been detected, to confirm the test's results and find the location of the tumor, Cance said. The EV-CLUE chips are created using a 3-D printer, in a process that could be distributed widely...
A tumour-naive assay, trained to detect residual cancer cells in blood, provided an earlier and more accurate warning of potential recurrence of colorectal cancer than current standard of care.
A multi-cancer blood test that helps identify cancer earlier for better outcomes. Powered by Artificial Intelligence. Get OneTest™ Check Your Risk Have a question? (240) 453-6339 HSA Accepted Get OneTest™ OneTest™ Standard OneTest™️ Standard includes5 or 6 cancer biomarkers:AFP, ...